JP2023528826A - Sars関連コロナウイルスに対する中和抗体 - Google Patents

Sars関連コロナウイルスに対する中和抗体 Download PDF

Info

Publication number
JP2023528826A
JP2023528826A JP2022573673A JP2022573673A JP2023528826A JP 2023528826 A JP2023528826 A JP 2023528826A JP 2022573673 A JP2022573673 A JP 2022573673A JP 2022573673 A JP2022573673 A JP 2022573673A JP 2023528826 A JP2023528826 A JP 2023528826A
Authority
JP
Japan
Prior art keywords
seq
amino acid
variable region
chain variable
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573673A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528826A5 (cg-RX-API-DMAC7.html
Inventor
シュテファン ベッカー
ヘニング グリュル
フロリアン クライン
クリストフ クレーア
マティアス ゼーナー
Original Assignee
ウニヴェルジテート・ツー・ケルン
フィリップス-ウニヴェルジテート マールブルク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウニヴェルジテート・ツー・ケルン, フィリップス-ウニヴェルジテート マールブルク filed Critical ウニヴェルジテート・ツー・ケルン
Publication of JP2023528826A publication Critical patent/JP2023528826A/ja
Publication of JP2023528826A5 publication Critical patent/JP2023528826A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2022573673A 2020-05-29 2021-05-28 Sars関連コロナウイルスに対する中和抗体 Pending JP2023528826A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20177354.6 2020-05-29
EP20177354 2020-05-29
EP20182325.9 2020-06-25
EP20182325 2020-06-25
EP20213562.0 2020-12-11
EP20213562 2020-12-11
PCT/EP2021/064326 WO2021239935A1 (en) 2020-05-29 2021-05-28 Neutralizing antibodies against sars-related coronavirus

Publications (2)

Publication Number Publication Date
JP2023528826A true JP2023528826A (ja) 2023-07-06
JP2023528826A5 JP2023528826A5 (cg-RX-API-DMAC7.html) 2024-06-05

Family

ID=76250344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573673A Pending JP2023528826A (ja) 2020-05-29 2021-05-28 Sars関連コロナウイルスに対する中和抗体

Country Status (6)

Country Link
US (1) US20210371503A1 (cg-RX-API-DMAC7.html)
EP (1) EP4157455A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023528826A (cg-RX-API-DMAC7.html)
CA (1) CA3180556A1 (cg-RX-API-DMAC7.html)
TW (1) TW202210504A (cg-RX-API-DMAC7.html)
WO (1) WO2021239935A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
MX2022014598A (es) 2020-05-26 2023-03-31 Regeneron Pharma Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
CR20220660A (es) 2020-06-03 2023-02-17 Regeneron Pharma Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2
EP4259200A1 (en) * 2020-12-11 2023-10-18 Boehringer Ingelheim International GmbH Formulation for multi-purpose application
AU2022221297A1 (en) * 2021-02-09 2023-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies targeting the spike protein of coronaviruses
WO2022263638A1 (en) * 2021-06-17 2022-12-22 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
EP4370210A1 (en) 2021-07-14 2024-05-22 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023150307A2 (en) * 2022-02-03 2023-08-10 Abpro Corporation Compositions and methods against a virus
CN118388640A (zh) * 2022-09-30 2024-07-26 郴州市第一人民医院 一种全人源抗新型冠状病毒SARS-CoV-2的广谱抗体及其应用
WO2025194069A1 (en) * 2024-03-15 2025-09-18 Atreca, Inc. Anti-csp antibody variants

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 感染性の呼吸性疾患の治療方法
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
ES2198922T3 (es) 1998-06-24 2004-02-01 Advanced Inhalation Research, Inc. Particulas porosas grandes emitadas por un inhalador.
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHI RUI ET AL.: "A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2", NATURE, vol. vol. 584 (7819), JPN6025025878, 26 May 2020 (2020-05-26), pages 120 - 124, ISSN: 0005792914 *

Also Published As

Publication number Publication date
WO2021239935A9 (en) 2023-07-13
EP4157455A1 (en) 2023-04-05
US20210371503A1 (en) 2021-12-02
TW202210504A (zh) 2022-03-16
CA3180556A1 (en) 2021-12-02
WO2021239935A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
TWI859420B (zh) 抗sars-cov-2抗體及使用其之方法
US20210371503A1 (en) Neutralizing antibodies against sars-related coronavirus
JP7498714B2 (ja) B型肝炎ウイルスを中和する抗体およびその使用
JP6412107B2 (ja) Rsvgタンパク質に結合するヒト抗体
KR20210075129A (ko) 삼중특이적 항-cd38, 항-cd28, 및 항-cd3 결합 단백질 및 바이러스 감염을 치료하기 위한 사용 방법
US20240059757A1 (en) Antibodies against sars-cov-2 and methods of using the same
CA2908921C (en) Human antibodies binding to rsv g protein
US20240336672A1 (en) Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof
CN114644708B (zh) 呼吸道合胞病毒特异性结合分子
JP2024507948A (ja) 呼吸器ウイルス感染症に対する防御抗体
CN116528897A (zh) 靶向SARS-CoV-2的抗原结合分子
US20250263467A1 (en) Antibody therapies for sars-cov-2 infection
WO2021218879A1 (zh) Sars-cov-2中和抗体及其制备和应用
US20220380441A1 (en) Antibody compositions and methods for treating hepatitis b virus infection
TW202144406A (zh) SARS-CoV-2抗體及其應用
WO2022051223A1 (en) Use of sars-cov-2 receptor binding motif (rbm)-reactive monoclonal antibodies to treat covid-19
US20230227539A1 (en) Methods and compositions related to neutralizing antibodies against human coronavirus
TW202440626A (zh) Sars-cov-2中和抗體
CN114761428B (zh) 抗血凝素抗体及其使用方法
WO2023288078A1 (en) Coronavirus antibodies and uses thereof
JP2024542793A (ja) Sars関連コロナウイルスに対する中和抗体
EP4190810A1 (en) Neutralizing antibodies against sars-related coronavirus
JP2024533166A (ja) 小児被験体におけるSARS-CoV-2感染の抗体療法
CN116724049A (zh) 针对sars相关冠状病毒的中和抗体
US20220073594A1 (en) Anti-sars-cov-2 neutralizing antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260210